Integrated analysis for drug repositioning in migraine using genetic evidence and claims database.

Front Big Data · 2025 · PMC12678156 · PMID 41355896

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Several agents, including nintedanib and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHi), also showed a trend toward protective effects (RR: 0.59, [95% CI: 0.32–1.09] and RR: 0.67, [95% CI: 0.34–1.29], respectively). 4 Discussion In this study, we used an integrative approach to identify potential therapeutic agents for migraine by leveraging genetic, perturbagen, and real-world claims databases.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.